

1 July 2024

Belluscura plc
("Belluscura" or the "Company")

Total Voting Rights

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the total number of Ordinary Shares in the capital of the Company in issue is 167,032,567 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the Company is 167,032,567. The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

For further information, please contact:

Belluscura plc

Robert Rauker, Chief Executive Officer
Simon Neicheril, Chief Financial Officer

www.belluscura.com

via MHP

SPARK Advisory Partners Limited
(NOMAD)

Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

Dowgate Capital Limited
(Broker)

James Serjeant / Russell Cook /
Nicholas Chambers

Tel: +44 (0)20 3903 7715

MHP Communications

(Financial PR and Investor Relations)

Katie Hunt / Matthew Taylor

Tel: +44 (0)20 3128 8100 / +44 7884 494112

Email: belluscura@mhpgroup.com

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRSSSFDFELSEFW